care into preoperative, intraoperative, and postoperative components, with the realization that there are overlapping indicators and measures of quality across these segments of care. Finally, in the scope of this review, we primarily focus on the surgical care of patients with early stage lung cancer and less on management of late-stage disease, including chemotherapy, immunotherapy, or targeted therapy. In addition, although it is becoming increasingly important, the role of patient reported outcomes is beyond the scope of this review.
ELEMENTS OF QUALITY AND VALUE Preoperative Assessment
At a minimum, preoperative evaluation should include computed tomography (CT) imaging to ascertain resectability and the extent of the resection required, pulmonary function testing to assess a patient's ability to tolerate the planned resection, and an assessment of a patient's performance status. 8 Previous studies have demonstrated that current smokers have a longer length of stay and increased risk of postoperative pulmonary complications. 8, 9 Therefore, smoking cessation should be strongly encouraged, and a program should be in place to provide support with both counseling and approved pharmacologic adjuncts. 8, 10, 11 All patients being considered for pulmonary resection should undergo preoperative pulmonary function testing, including spirometry and diffusion capacity. 12, 13 Predicted postoperative forced expiratory volume in 1 second and diffusing capacity of the lungs for carbon monoxide should be calculated. Patients with a predicted postoperative value < 40% for either measurement should be considered high-risk for lobectomy and should be offered either sublobar resection or nonsurgical therapy. For selected patients with marginal pulmonary function testing results, cardiopulmonary exercise testing can be performed to assess suitability for resection.
In general, preoperative cardiac testing should be limited to patients with significant risk factors for cardiac disease. Although no randomized studies have evaluated the role of preoperative coronary revascularization before lung resection, randomized trials from the vascular surgery population-an arguably similar group of patients to those undergoing lung resection-do not support preoperative revascularization for patients with stable cardiac disease. 14 The American College of Cardiology and the American Heart Association have jointly published guidelines for the perioperative evaluation of patients undergoing noncardiac surgery. 15 The STS and National Quality Forum endorse recording performance status and clinical stage before lung resection as preoperative process measures. Reduced preoperative performance status has been associated with an increased perioperative risk of morbidity and mortality. 5 Similarly, clinical stage has been linked to short-and long-term postoperative outcomes. As such, both of these measures should be recorded for all patients undergoing lung resection for presumed or biopsy-proven lung cancer.
Preoperative Staging
In a retrospective study of the Surveillance, Epidemiology, and End Results (SEER) database, Ost and colleagues 16 evaluated patients with lung cancer with regional spread but without evidence of metastatic disease and found that only 21% had a diagnostic evaluation consistent with the established guidelines. Only 56% of patients in this study underwent mediastinal sampling before treatment. 16 Farjah and colleagues 17 also demonstrated reduced survival among Medicare recipients who did not receive preoperative mediastinal staging in accordance with the existing guidelines.
Several clinical guidelines for preoperative staging exist, but the most comprehensive are those published by the NCCN (Table 1) . 18 In addition to a CT scan of the chest and upper abdomen, a positron-emission tomography/CT scan should be obtained to assess for evidence of metastatic disease. Pathologic mediastinal lymph node evaluation should be performed before lung resection for central stage IA tumors and all stage IB to stage IIIA tumors, using the least-invasive means possible. Pathologic mediastinal staging should also be performed for peripheral stage IA tumors when there is hilar or mediastinal adenopathy and/ or fluorodeoxyglucose avidity in these lymph nodes on positron-emission tomography scan. 18 The ESTS has developed detailed, evidenced-based guidelines for the preoperative staging of mediastinal lymph nodes in patients with non-small cell lung cancer (NSCLC). 19 In accordance with NCCN guidelines, a magnetic resonance imaging brain scan with contrast should be obtained preoperatively for all patients with small cell lung cancer or stage II to stage IV NSCLC, to assess for evidence of brain metastasis. 18 For cases where brain magnetic resonance imaging is not available or not possible, a head CT with contrast is recommended. 24 Despite these findings, there have been no reported differences in overall survival, disease-specific survival, or progressionfree survival in patients who underwent minimally invasive lobectomy versus open thoracotomy. Therefore, minimally invasive approaches have significant early advantages for patient care; however, the current literature does not support the oncologic superiority of one approach over the other.
Cost of procedure has become an increasingly important consideration when assessing quality in this new era of value-driven care. A comparison of costs between VATS lobectomy and thoracotomy found that VATS lobectomy costs about $3476 less than thoracotomy. This cost difference was attributed primarily to shorter length of stay in the VATS cohort. 25 Compared with those for traditional VATS, the current costs for robot-assisted VATS make it less appealing from a pure value proposition perspective. 26 Moreover, a recent meta-analysis demonstrated equivalency in both short-and long-term outcomes for these 2 minimally invasive approaches. 27 Therefore, at present the cost differential and the similar Thoracic: Lung Cancer: Feature Expert Opinion Brandt, Isbell, Jones early benefits in patient care suggest that VATS offers the best value (cost/outcome) of these 2 approaches; however, robot-assisted VATS remains a relatively new technology, and with time and increased robotic platform competition costs will likely decrease.
Resection and margins. Although no prospective trials have compared outcomes between R0 and R1 resection, R1 resection is an independent predictive factor for poor prognosis and is associated with lower 5-year overall survival. 28 A recent best evidence analysis of>400 reports suggested that, following incomplete resection, patients with microscopic (R1) or nodal residual disease have a survival advantage over those with macroscopic residual (R2) disease. 29 To minimize the incidence of recurrence and to raise awareness about the importance of achieving negative margins, we recommend institutional tracking and scheduled review of R1 and R2 resections for lung cancer, preferably stratified by type of resection.
Surgeons must decide the most oncologically superior type of resection to perform. Lung Cancer Study Group 821 established lobectomy as the current standard of care for early stage, node-negative operable lung cancer. 30 The majority of contemporary publications show a significant reduction in overall and disease-free survivals when sublobar resection is performed instead of lobectomy. 31, 32 Furthermore, examination of the National Cancer Database (NCDB) (2003) (2004) (2005) (2006) (2007) (2008) (2009) (2010) (2011) revealed that patients with cT1 N0 M0 tumors undergoing sublobar resection were more likely to receive inadequate lymphadenectomy and have positive margins. 32 CALGB 140503 and Japan Clinical Oncology Group 0802 are prospective, randomized noninferiority trials examining lobectomy versus sublobar resection; mature results are due after 2020. Japan Clinical Oncology Group 0802 permits only segmentectomy, whereas CALGB 140503 permits wedge resection and segmentectomy, which may make interpretation of the results more challenging. Until the mature results of these clinical trials are published, the best level-1 evidence-although it is older-demonstrates that lobectomy offers the largest oncologic benefit for patients with early stage lung cancer. For patients who are not candidates for lobectomy, the preponderance of level-2 evidence suggests that segmentectomy is oncologically superior to wedge resection for the treatment of smaller tumors. 31, 33 Additional evidence and current American College of Chest Physicians guidelines suggest that patients who cannot tolerate lobectomy are candidates for sublobar resection or stereotactic body radiation therapy. 34, 35 Resection margin is a useful intraoperative quality metric with relevance to tumor recurrence, particularly in sublobar resections. A comprehensive retrospective analysis demonstrated that, in patients with tumors smaller than 2 cm who underwent wedge resection for NSCLC, the risk of local recurrence was significantly decreased with increasing margin distance up to 15 mm. 36 Additional studies of patients who underwent segmentectomy found that margins 1 cm were associated with an increased risk of local recurrence. 37 These data and the findings from other studies support efforts to achieve a resection margin of 2 cm in patients undergoing surgery for NSCLC. Lymph node evaluation. Adequate lymph node evaluation is among the most critical elements of a quality lung cancer operation. As Osarogiagbon and colleagues showed in their examination of several large databases, 38 including the California Cancer Registry, the SEER database, and the NCDB, appropriate pathologic nodal staging of NSCLC is critically underutilized. Since then, multiple retrospective studies have been performed. The findings demonstrate that, in pN0 resection specimens, a median of 5 lymph nodes were examined 39 ; in 12% of all resections, and in 18% of all node-negative resections, no lymph nodes were examined [39] [40] [41] [42] ; among pN0 cases, 12% had no N1 lymph nodes examined 43 ; in 42% of resections, and in 62% of mediastinal lymph node-negative cases, no mediastinal lymph nodes were examined. 39, 40, 44, 45 Multiple guidelines on what constitutes an adequate nodal dissection are available to intraoperatively guide surgeons ( Table 2 ). The American College of Surgeons Commission on Cancer has focused on the number of lymph nodes removed as a quality surrogate; however, we prefer and recommend using the International Association for the Study of Lung Cancer nodal maps, which focus on nodal stations, for pre-and intraoperative nodal staging. Although selective lobar-specific N2 nodal staging 46 or N2 nodal sampling 47 strategies appear to have oncologic equivalence to nodal dissection for clinical stage I lung cancer, we favor systematic mediastinal lymphadenectomy, as defined by ESTS guidelines, 48 regardless of the surgical approach used. Logical exceptions to this approach include minimally invasive adenocarcinoma and adenocarcinoma in situ histologic subtypes and T1a tumors. Regardless of whether lymph nodes are sampled or dissected, we believe that systematic acquisition of mediastinal nodal tissue based on nodal station(s) is a useful quality metric, and, therefore, we recommend each program adopt a preferred approach and track adherence.
Postoperative Quality Measures
Morbidity and mortality. The outcome measures of morbidity and mortality are dependent on appropriate case selection, the need for induction therapy, surgical technique, and strategies to mitigate failure to rescue concerns. 49 A quality program should track 30-day or in-hospital mortality as well as 90-day mortality following lung cancer resection. Some authors have questioned whether 30-day or in-hospital mortality should be used as a quality metric, on the basis of low occurrence rates and the fact that mortality doubles at 90 days, which suggests it is not a worthwhile discriminator between good-and poor-performing programs. 50 In addition, relevant morbidities that influence quality of care and the patient experience, such as pneumonia, deep vein thrombosis or pulmonary emboli, reoperation, and persistent air leaks, should be measured and tracked. Using the STS database, Kozower and colleagues 51 combined risk-adjusted morbidity and mortality into a 2-domain composite score to rate program performance. 51 Although imperfect, morbidity and mortality metrics with appropriate reliability and clinical utility that are risk-stratified do exist and can serve as starting points for quality improvement projects or related initiatives for individual programs (Table 3) .
Length of stay following lung cancer resection remains an important surrogate quality metric. Although surgical approach has no significant effect on mortality, the majority of the literature supports the perspective that minimally invasive approaches result in fewer complications and shorter length of stay, without increasing readmission rates. This suggests that increasing (and measuring) the percentage of minimally invasive approaches performed for early stage disease (stage I or stage II) as a process measure may result in decreased lengths of stay and improve value. The percentage of minimally invasive resections performed for clinical stage I lung cancer currently stands at 64% in the STS database, and this is now a metric that is captured and reported. 51 Finally, exclusive of the development of perioperative complications, length of stay is strongly affected by patient comorbidities, age, and socioeconomic status. Length-of-stay metrics likely need to be riskstratified on the basis of these and other variables to be meaningful to a practicing surgeon. Enhanced recovery after surgery. Initiated in the 1990s by Kehlet 53 and others, enhanced recovery after surgery (ERAS) protocols are multimodality pathways designed to decrease the physiologic and psychological effects of surgery, reduce length of stay and complications, and facilitate recovery. The primary components of these process improvement programs are focused on preoperative nutrition, nonopioid analgesia, limited perioperative fluid administration, and early ambulation. 54 Muehling and colleagues 55 investigated an ERAS protocol and found no significant reductions in mortality, readmission rates, or complications (excluding a reduction in pulmonary complications). 55 A recent meta-analysis using a Cochrane risk-for-bias model resulted in low-quality evidence suggesting that an ERAS program for pulmonary resection reduces length of stay. 56 However, costs were reduced in 2 of the 3 studies in which this was examined, and patientreported outcomes were also improved in the one study that examined this variable. 56 In summary, the influence of ERAS programs on enhancing quality is understudied 
Guideline
Anatomic resection is preferred for the majority of patients For patients who undergo segmentectomy or wedge resection, the patient should have resection margins 2 cm or that are greater than or equal to the size of the nodule Segmentectomy or wedge resection is appropriate for patients with poor pulmonary reserve and with peripheral nodule 2 cm with any of the following: pure adenocarcinoma in situ histologic subtype, nodule 50% ground glass appearance on computed tomography, or radiologic surveillance with long doubling time (400 d) Minimally invasive approaches should be performed in appropriate patients N1 and N2 node assessment should be performed with a minimum of 3 N2 stations or with complete nodal dissection Formal ipsilateral mediastinal lymph node dissection is indicated for patients undergoing resection for stage IIIA disease Complete resection requires resection-free margins, systematic lymph node dissection or sampling, and appropriate mediastinal node dissection Thoracic: Lung Cancer: Feature Expert Opinion Brandt, Isbell, Jones in thoracic surgical oncology. Opportunities exist to perform well-designed randomized trials to clarify the role of ERAS programs in our specialty.
Hospital Readmission
Reduction of hospital readmission is a priority for surgeons; hospitals; insurers; and, most importantly, patients. An unintended consequence of efforts to reduce length of stay may be increased readmission rates, with most data suggesting a U-shaped relationship between length of stay and readmission rates. 57 However, a recent study using the NCDB showed that early discharge strategies do not increase readmission rates among patients who have undergone open or minimally invasive lobectomy for lung cancer. 58 Several studies have examined hospital readmission rates following pulmonary resection. A recent article linked 3 administrative databases and found that the overall readmission rate in the Medicare population following lobectomy is 12%. 59 Hospital Quality Alliance surgical score, procedure volume, and 30-day surgical mortality were used to determine whether measures of surgical quality affected readmission rates. Hospital Quality Alliance surgical score is calculated according to the evidence-based Surgical Care Improvement Project process measures, which are designed to reduce perioperative surgical complications and are included in the Centers for Medicare and Medicaid Services Hospital Value-Based Purchasing program. 59 For 1602 hospitals spanning both high-and low-volume centers (N ¼ 24,316 patients), only hospital volume was significantly associated with 30-day readmission rates following lobectomy. Another analysis of the SEER database revealed a 13% readmission rate following lung cancer resection, which was associated with a 6-fold increase in 90-day mortality. 50 Other groups have shown that the 90-day readmission rate following lung cancer resection is 21%, with only 81% of patients discharged home after their index procedure. 60 Collectively, these data show that efforts to reduce hospital readmission following lung cancer resection are influenced by procedure type, hospital volume, patient socioeconomic status, discharge destination, and index procedure length of stay. Some of these risk factors may be modified, but many cannot be modified, which makes addressing this outcome metric challenging. Nonetheless, we believe that readmission rates following NSCLC resection should be considered a quality metric, and institutional rates should be tracked and analyzed.
Consideration of Adjuvant Therapies
Although it is not a primary focus of this review, appropriate referral for adjuvant therapies following lung cancer resection is an important element of lung cancer care. For instance, clear consensus-based guidelines exist both for referral for adjuvant chemotherapy for pathologic node-positive disease and for consideration of adjuvant radiation to the mediastinum for persistent or intraoperatively discovered N2 disease. 13 Therefore, programmatic oncologic quality metrics to track appropriate and inappropriate referrals for adjuvant therapy and the number of patients who complete such therapy are important.
CONCLUSIONS
Quality in the surgical care of patients with lung cancer is a complicated, multidimensional, and moving target. There is an emerging body of evidence showing that an understanding of and adherence to known quality metrics in thoracic oncologic surgery results in improved patient outcomes. Some groups have developed systems to evaluate and improve quality, such as the Composite Performance Score. 61 This concept was recently illustrated in a study by Samson and colleagues, 62 who examined the use of 4 well-established quality metrics in the management of stage IIIA NSCLC. Adherence to all quality metrics resulted in a significant improvement in overall survival. 62 A robust opportunity remains for thoracic oncologic surgeons to design and conduct quality initiatives and to report on how they influence the patient experience and patient outcomes. The structure to complete these types of projects is always multidisciplinary and is most commonly housed in a disease management team or related entity. Establishment of a quality thoracic surgical program begins with deciding what quality metrics are important to collect and analyze and are modifiable through practice changes, and then linking them to a desired outcome. The STS has suggested participation in a national or regional database as a quality metric, and there are clear benefits to benchmarking your program to others. Although the emerging relationship between quality and hospital volume is beyond the scope of this article, we believe that the highest-quality programs will have the best patient outcomes and value and that, when controlling for access, quality will be the ultimate driver of patient volumes.
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